Advanced Therapies For Common Conditions In England Won’t Get Extra Funding, Says Ex-NICE Official

 
• By Eliza Slawther

Health technology assessment agencies are willing to pay more than usual for advanced therapies that treat rare or severe diseases, but an advanced therapy for a common condition would not qualify for such a modifier, a former senior figure at England’s NICE says.

NICE bases its payment modifiers on the intended patient population, not the therapy itself (Shutterstock)

More from Cell & Gene Therapies

More from Advanced Technologies